CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00620139
NCT00620139N/ACompleted
CompareCT.gov

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

Memorial Sloan Kettering Cancer Center·observational·Posted Feb 21, 2008·Updated Oct 24, 2013

In Brief

An observational study evaluating the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis, for Head and Neck Squamous Cell Carcinoma. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This pilot study seeks to evaluate the feasibility of measuring the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic target molecules in Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, this study proposes to evaluate the extent to which CRT induces the differential expression of components along two critical, and potentially interdependent, molecular pathways: the arachidonic acid and epidermal growth factor receptor (EGFR) signaling pathways.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 21, 2008
Enrollment StartMar 1, 2005
Primary CompletionOct 1, 2013
TodayJul 1, 2026
Enrollment to primary: 8.6 yearsPosted 18.4 years ago

Interventions

the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,biological

patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.